Stem Cell Clinic

2020-2025 Global and Regional Stem Cell Alopecia Treatment Industry Production, Sales and Consumption Status and Prospects Professional Market…

By Stem Cell Treatment

The global Stem Cell Alopecia Treatment market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Stem Cell Alopecia Treatment market, offers profound understandings about the Stem Cell Alopecia Treatment market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Stem Cell Alopecia Treatment focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4359779

Manufacturer Detail

By Market Players:

By Application

By TypeAlopecia Areata, Alopecia Totalis, Alopecia Universalis

The Stem Cell Alopecia Treatment market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Stem Cell Alopecia Treatment market. This report on Stem Cell Alopecia Treatment has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Stem Cell Alopecia Treatment research study by HNY Research offers collection of information and analysis for each facet of the Stem Cell Alopecia Treatment market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-uterine-fibroids-treatment-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Stem Cell Alopecia Treatment report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4359779

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read more from the original source:
2020-2025 Global and Regional Stem Cell Alopecia Treatment Industry Production, Sales and Consumption Status and Prospects Professional Market...

Researchers found a cure for diabetes (in lab mice) – The Next Web

By Stem Cell Treatment

More than 34 million Americans have diabetes, approximately 10% of the population according to the American Diabetes Association. To date, the most common treatment has been to manage the disease with a carefully controlled diet and regular insulin shots, if needed. But a cure may be on the horizon.

A research team led by Jeffrey Millman at Washington University in St. Louis, Missouri found last year that infusing mice with stem cells could offer a better treatment option.

Building on that research, the same team may have found a cure: at least in lab mice.

Diabetics are characterized by their difficulty producing or managing insulin. This requires careful monitoring, a strict diet, exercise, and expensive insulin shots which many diabetics find themselves rationing due to the cost of drugs in the United States. Insulin is normally produced in the pancreas, but those with diabetes dont produce enough of it. To treat diabetes, many diabetics have to monitor their blood sugar levels, and inject insulin directly into the bloodstream as needed. Millmans treatment foregoes these shots and instead uses beta cells to secrete the insulin for you.

The treatment relies on induced pluripotent stem cells (iPS cells). These cells are essentially a blank slate and can be tricked into becoming almost any other type of cell in the body.

In a new study, the team improved on the technique it had developed last year to produce and introduce these cells into the bloodstream. When converting the stem cells into another type of cell, there are always mistakes and random cells enter into the mix along with the insulin-producing ones. These cells are harmless, but they dont pull their weight.

The more off-target cells you get, the less therapeutically relevant cells you have, Millman told New Atlas. You need about a billion beta cells to cure a person of diabetes. But if a quarter of the cells you make are actually liver cells or other pancreas cells, instead of needing a billion cells, youll need 1.25 billion. It makes curing the disease 25% more difficult.

The new method would rid the sample of those unwanted cells. Millmans team built a process that targeted the cytoskeleton, the structure that gives the cells their shape, and produced not only a higher percentage of effective beta cells, but better functioning ones.

When these new cells were infused into diabetic mice, their blood sugar levels stabilized, leaving them functionally cured of the disease for up to nine months.

Granted, its just an animal trial. The results shouldnt be interpreted as a cure for humans. But its a promising start.

The team plans to continue testing the cells in larger animals, and over longer periods, with their sights set on human clinical trials in the future.

Read next: Smithsonian Institute just released 2.8 million high-quality images for free

See the original post:
Researchers found a cure for diabetes (in lab mice) - The Next Web

United Therapeutics: Buy The Dip – Seeking Alpha

By Stem Cell Treatment

On February 26, United Therapeutics (UTHR) came out with earnings results for the fourth quarter of 2019. The companys revenues of $311.11 million were down YoY by 18.43% and fell short of the consensus by $46.06 million. The companys fourth-quarter non-GAAP EPS (earnings per share) of $1.96 also missed the consensus by $1.43.

Subsequently, the stock is down by 11.97% from $112.86 on February 25 to $100.79 on February 27. I believe that this is an investor overreaction, considering that the dip in revenues and EPS is associated with a one-time event of inventory destocking by a distributor in the fourth quarter. Earlier in 2019, this distributor had placed larger-than-normal orders for the companys products due to an error in its patient utilization data. Hence, the smaller-than-normal order in the fourth quarter was an attempt to normalize inventory levels.

Besides this small glitch, the company boasts of robust fundamentals. Today, we will see why United Therapeutics can prove to be an attractive opportunity in 2020.

United Therapeutics is a biotechnology company focused on developing novel, life-extending therapies in lung disease, oncology, and organ manufacturing indications. The company commercializes therapies including an infused formulation of the prostacyclin analog treprostinil, Remodulin; an inhaled formulation of treprostinil, Tyvaso, and a tablet dosage form of treprostinil, Orenitram; and an oral PDE-5 inhibitor, Adcirca, in PAH (pulmonary arterial hypertension) indication. The company also offers Unituxin, a monoclonal antibody for treating neuroblastoma.

United Therapeutics is now working on developing next-generation technologies for Remodulin, Tyvaso, and Orenitram. The companys R&D pipeline also has investigational novel biologics and NCEs (new chemical entities) targeting various lung, oncology, and organ manufacturing indications.

In July 2002, the company secured FDA approval for Remodulin as a continuous subcutaneous infusion for the treatment of PAH patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. Despite the launch of a generic treprostinil in early 2019, Remodulins sales were only 2% down YoY to $587 million in 2019. In fact, the company reported the highest number of new Remodulin starts in the last ten years.

The YoY decline in Remodulin sales was attributed to a small number of patients switching to the generic drug, as well as to the fact that new patients start on lower dosages of Remodulin and then begin the process of titrating to their effective dose. Since the patient switching trend has all but trickled down, the company now expects U.S. Remodulin patient demand as well as sales to jump up YoY in 2020.

Remodulin demand has been pretty sticky for years. It is a very complex product targeting a very fragile patient population, which places a high premium on years of safety and supply chain reliability.

United Therapeutics is now getting ready to launch the subcutaneous delivery system for Remodulin injections, the RemUnity system, in July 2020. Co-developed by United Therapeutics and Deka Research and Development and cleared by FDA under the FDA 510(K) pathway, the RemUnity system is expected to reduce the risk of bolus dosing due to pump failures and provides wider arrays of notifications, alerts, and alarms than current pumps. Additionally, the RemUnity system will control Remodulin flow rates without the use of a motor. The pump is small and lightweight with a service life of at least three years.

On February 24, the company announced preliminary analysis from Phase 3 INCREASE study evaluating Tyvaso Inhalation Solution in patients suffering from WHO (World Health Organization) Group 3 pulmonary hypertension associated with PH-ILD (interstitial lung disease). The trial met its primary endpoint of demonstrating improvement in 6MWD (six-minute walk distance). In addition to increasing six-minute walk distance by 21 meters versus placebo after 16 weeks of treatment, Tyvaso also demonstrated significant improvements in each of the study's secondary endpoints, including reduction in the cardiac biomarker NT-proBNP, time to first clinical worsening event, change in peak 6MWD at Week 12, and change in trough 6MWD at week 15. Based on the INCREASE results, the company now plans to submit a supplemental new drug application to expand the Tyvasos label in mid-2020.

In June 2019, the company submitted a 505(B)(1) NDA (new drug application) for Trevyent disposable treprostinil pump system. Although the FDA first accepted the application and set PDUFA (prescription drug user fee act) date as April 27, 2020, the agency later included a mid-cycle information request noting several deficiencies in the Trevyent NDA. While the company has already sent its responses to the FDA, based on recent discussions with the FDA, the company expects a delay in the PDUFA date. The company expects this FDA approval in the next 18 months.

United Therapeutics also expects the launch of ISR (Implantable System for Remodulin) codeveloped with Medtronic (MDT) to be delayed to 2021. The delay of the commercial launch is attributable to Medtronic satisfying various conditions to its PMA approval.

United Therapeutics estimates the prevalence of PAH WHO Group 1 in the U.S. to be more than 45,000. The currently approved PAH drugs are for PAH WHO 1 class patients. According to PHA (Pulmonary Hypertension Association), WHO Group 1 refers to pulmonary arterial hypertension (PAH), which is caused when the arteries in the lungs become narrowed, thickened or stiff. The right side of the heart must work harder to push blood through these narrowed arteries. This extra stress can cause the heart to lose its ability to pump enough blood through the lungs to meet the needs of the rest of the body.

However, the prevalence of PAH WHO Group 3 patients in the U.S is even higher, of around more than 130,000 patients. These patients do not have any FDA approved treatment option. Again, according to PHA, WHO Group 3 includes PH due to chronic lung disease and/or hypoxia (low oxygen levels). These lung diseases include obstructive lung disease where the lung airways narrow and make it harder to exhale (e.g. COPD or emphysema); restrictive lung disease in which the lungs have a tough time expanding when one inhales (e.g. interstitial lung disease or pulmonary fibrosis); sleep apnea, and living in an area of high altitude for a long period of time. Arteries in the lungs tighten so that blood can only go to areas of the lungs that are receiving the most air and oxygen. This tightening leads to high blood pressure throughout the lungs.

United Therapeutics is working to increase its total patient base from around 7,500 to 25,000 in the next five years.

Besides Remodulin, Tyvaso and Orenitram also saw the highest patient demand in 2019 as compared to the last four years.

Then again, United Therapeutics expects RemUnity, Trevyent, ISR, and Smart Pump technology to have a very favorable impact on future patient demand and sales of Remodulin. The company also expects label expansion of Tyvaso based on the INCREASE study to increase the addressable U.S. population by more than 30,000 patients. This will also position the Tyvaso as a treatment option for a section of the PAH WHO Group 3 patients, those with interstitial lung disease. The company is studying Tyvaso in COPD (chronic obstructive pulmonary disorder) patients in the Phase 3 PERFECT study. Finally, the expanded label of Orenitram based on the FREEDOM-EV trial highlighting superior morbidity and mortality outcomes is also helping to attract new PAH patients.

United Therapeutics is now studying Tyvaso in PH WHO Group 3 patients, PH COPD patients, in Phase 3 trial PERFECT. The company seems to have high hopes for the success of the trial after robust results from the INCREASE study since inhaled therapies can avoid the VQ (Ventilation Perfusion Mismatch), as is seen in system therapies targeting lung diseases. The PERFECT trial is currently 20% enrolled.

Besides studying already approved products for additional indications, the company also has a slew of investigational NCEs and biologics in its pipeline.

United Therapeutics expects investigational Phase 3 asset, ralinepag, to transform the care of WHO Group I PH patients. The company is also studying a gene therapy study in the Phase 3 trial, SAPPHIRE, to make PH treatment more convenient with just a once quarterly infusion of genetically engineered autologous stem cells from the patient. The company expects enrollment to be completed in 2021, and product launch by 2025. Finally, the company is attempting its hand at the much challenging and lucrative organ manufacturing segment.

The biggest risk weighing down on United Therapeutics valuation is the potential impact of generic erosion of Remodulin. The company depends extensively on its topline on the treprostinil franchise, exposing it to significant business concentration risk.

The company is exposed to R&D failure risk and subsequent contraction in probable growth drivers. The most recent example of such a failed trial is the phase 2/3 DISTINCT study evaluating Unituxin in Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory SCLC (small cell lung cancer). On February 3, 2020, the company announced that this trial did not meet its primary endpoint of extending OS (overall survival).

According to finviz, the 12-month consensus target price of the company is $122.22. On February 27, Cowen analyst Chris Shibutani upgraded United Therapeutics from Market Perform to Outperform and raised the price target from $119 to $145. On February 25, Wedbush analyst Liana Moussatos raised her price target from $237 to $243 and reiterated Outperform rating for the stock. On February 13, Credit Suisse analyst Martin Auster reiterated the Outperform rating and raised his price target from $113 to $121. On January 31, JPMorgan analyst Jessica Fye revised upwards United Therapeutics rating from Neutral to Overweight and price target from $116 to $120. On December 27, Oppenheimer analyst Hartaj Singh reiterated the Outperform rating and $155 target price.

We see that the overall analyst sentiment and target price have consistently improved for the company since March 2019.

Based on the companys robust product portfolio, strong pipeline, and multiple upcoming catalysts, I believe that $145 is a fair estimate of the true value of the company. I believe that retail investors with above-average risk appetite should consider buying the company on the latest dip in 2020.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more here:
United Therapeutics: Buy The Dip - Seeking Alpha

25 new Android games from the week of February 24, 2020 – Android Police

By Stem Cell Doctors

Welcome to our roundup of the new Android games that went live in the Play Store or were spotted by us in the previous week or so. Today I have the official launch of Valve's auto chess title, the Western release of a Dragon Quest gacha game, the soft launch of Electronic Arts' tower defense game Plants vs. Zombies 3, and the arrival of LEGO's free-to-play hero brawler. So without further ado, here are the more notable Android games released during the week of February 24th, 2020.

Looking for the previous roundup editions? Find them here.

Android Police coverage: Valve's Auto Chess competitor Dota Underlords is coming to Android (Update: Season 1 starts today)

Dota Underlords is Valve's take on auto chess, built off of the MOBA Dota 2, and it's been playable on Android since July 2019, though this week marks the official release as well as the beginning of the first season for the title. As expected, the auto-battler offers a $5 subscription pass for anyone that would like to earn extra rewards as they play, and since this week marks the official stable release for mobile, new modes and gameplay elements have arrived to flesh out the title. Sadly, many reviews point to poor balancing, which is something to keep in mind if you haven't played this auto-battler yet.

Monetization: free / no ads / IAPs from $0.99 - $4.99

Android Police coverage: Dragon Quest of the Stars is available for download a day early, but you can't play it yet (Update: Out now)

Dragon Quest of the Stars is a four-year-old mobile RPG from Square Enix that has just made its way to the West. It brings along aging art and game design, and yet includes exorbitant in-app purchases, not to mention a monthly sub that locks ease-of-use features behind a paywall. So not only is this game a cash-in, it's not even new. So while the gacha-based gameplay assuredly offers an addictive grind, expect to pay through the nose if you'd like to advance at a regular pace.

Monetization: free / no ads / IAPs from $0.99 - $79.99

Android Police coverage: Plants vs. Zombies 3 leaves pre-alpha testing, enters soft launch in select territories

This week Plants vs. Zombies 3 left pre-alpha and entered into a soft-launch phase. Right now, the game is officially available in the Philippines and should be coming to new regions as the days move forward, though an in-depth time frame hasn't been provided. So it would seem Electronic Arts is slowly pushing Pv3 out to the public as it continues developing and testing the game to ensure that fans will love it. Of course, if you check out the listed in-app purchase prices below, it's easy to understand why it could be challenging for many fans of the series to get excited about this title.

Monetization: free / contains ads / IAPs from $0.99 - $99.99

Android Police coverage: LEGO Legacy: Heroes Unboxed is a F2P collect-a-thon RPG, now available on the Play Store (Update)

LEGO Legacy: Heroes Unboxed is a free-to-play strategy RPG that stars everyone's favorite LEGO characters, and that's on purpose since this a hero collection game. Yep, if you've ever playedMARVEL Strike Force,Star Wars: Galaxy of Heroes,DC Legends: Battle for Justice,Ninja Turtles: Legends,Disney Heroes: Battle Mode,Looney Tunes World of Mayhem,Might and Magic: Elemental Guardians,Age of Magic, orSummoners War, then you should know exactly what to expect from Heroes Unboxed. More or less, it's a kids game filled with gambling mechanics disguised as mini-figure collecting, which shows LEGO has no qualms emptying the pockets of children for its profits.

Monetization: free / no ads / IAPs from $0.99 - $99.99

ISOLAND 3: Dust of the Universe is the long-awaited sequel to Isoland 2: Ashes of Time, though it looks like the dev opted for a different publisher this time around. More or less, you can expect the same fantastic point-and-click adventure gameplay as the first two titles in the series, all wrapped up in a new story that explores the significance of art.

Monetization: $1.99 / no ads / IAPs from $0.99 - $4.49

Story of a Gladiator is a new release from the creators of Dark Quest and its sequel. Unlike the developer's previous titles, Story of a Gladiator isn't an RPG. It's actually a brawler similar in style to Capcom's beat 'em up games. Of course, this title is themed around fighting in an arena as a gladiator, and it offers 80 enemies, three arenas, 36 battles, and three boss fights. So if you're looking for a quality arcade brawler that won't break the bank, Story of a Gladiator is a solid choice.

Monetization: $2.99 / no ads / no IAPs

Aces of the Luftwaffe - Squadron: Extended Edition offers two separate titles in a single package, which explains the $7.99 price tag. As you would expect, this is a top-down shoot 'em up, and it's themed around the planes that took to the air in WWII. Since the game offers two separate campaigns, you can expect to shoot your way through 50 levels and 12 boss fights. Best of all, the entire game is fully voiced, which adds a level of polish you wouldn't expect from a mobile release. If you love top-down arcade shooters, this one's worth the asking price.

Monetization: $7.99 / no ads / no IAPs

Eri's Forest is an extremely unique tower defense game that offers a 360-degree playing field. Essentially each match will take place on a piece of a tree, and you'll have to revolve the camera around this branch to get a clear picture of the entire field. This makes for exciting matches since you'll have to micromanage your camera as you keep the baddies from reaching your base. This is how you take a tried and true genre and turn it on its head, folksprops to the dev.

Monetization: $7.99 / no ads / no IAPs

SWORDSHOT Demo serves as an early access release for what is essentially a top-down shooter. The thing is, this is a static shooter, and so it will be your job to blast the revolving shields of your enemies in order to take them down. Think of the game as a boss rush mode in your favorite top-down shooter, and that's precisely what you can expect from this release.

Monetization: free / no ads / no IAPs

The Cat in the Hat Invents: PreK STEM Robot Games is an educational game designed to get kids interested in STEM. Of course, most STEM fields require a massive amount of dedication to be successful in them, so it's not like the Cat in the Hat is going to all of a sudden make your kid good at math, but I suppose stoking interests early is still a good thing.

Monetization: free / no ads / no IAPs

This is a bit of an odder listing, but it would appear that Dish Life: The Game is a simulation title all about growing stem cells, of all things. It will be your job to manage the daily activities of a stem cell lab, such as growing and nurturing stem cells. Of course, this is also a game that contains a political bend, so subjects like politics and social issues are present for some reason. Oh, and like most games that were built to focus on a political message instead of fun, this is a title filled with bugs. Imagine that.

Monetization: free / contains ads / no IAPs

Dungeon Quest Action RPG is chiefly a hack-and-slash dungeon crawler that exudes a few roguelike elements. Players will have to level up as they collect new equipment, and there are a few boss fights in the mix, so players should expect a challenge. Best of all, this title isn't some greedy gacha game, so its monetization is straightforward. If you like what you see, you can purchase the entirety of the title through a single in-app purchase.

Monetization: free / contains ads / IAPs $3.49 a piece

Make it perfect is a game for everyone out there that suffers from OCD. I know that I have a peculiar problem where I can't fall asleep if my shoes aren't standing up straight on the floor, and so I can totally get behind a game that's all about unnecessary perfection and tidiness. Essentially it will be your job to clean up each level in the game to the point where things look perfect. Then it's on to the next stage.

Monetization: free / contains ads / IAPs $3.49 a piece

US Conflict is a real-time strategy game that forgoes the general BS you would expect of a mobile RTS title. That means this release offers gameplay that is closer to what you would expect from a PC RTS game, all in the palm of your hands. Really, the only downside I can find with this release is that there are only 12 stages to play through, making for a short experience, but still a fun one.

Monetization: free / contains ads / IAPs $5.99 a piece

It would appear that ZeptoLab has fallen to the wayside much like Rovio, and is now releasing shallow junk, like this endless runner. Maybe if ZeptoLab had jumped into the genre when it was still popular, this release would make more sense, but seeing that this style of game is completely played out, I have to wonder who greenlit this release. I mean, the title works as advertised, but really who cares about yet another pointless endless runner, even if it stars a cute character from a 10-year old mobile game. At the very least, the title's in-app purchases aren't all that bad. It's just a shame ZeptoLab couldn't come up with an original idea.

Monetization: free / contains ads / IAPs from $0.99 - $9.99

Microsoft Sudoku is a release that caught me by surprise. Up until this week, I never heard about the game, but it would appear that's it's been around for a while on competing platforms. Still, it's a surprise to see the title appear on the Play Store without word-one from Microsoft, and it would seem that more than a few people have been able to play the game over the last few months, and so far many of the reviews point to sound bugs and iffy controls.

Monetization: free / contains ads / IAPs from $1.99 - $9.99

Do you love adorable cats? Do you enjoy playing idle games? Well, guess what, Idle Cat Stars is an infectious title that contains both, and it just entered into early access this week. Essentially this is a celebrity cat management game, and so it will be your job to direct the careers of famous felines, such as Angry Cat. So if you'd like to experience what it's like to run the social media campaign for your favorite celebrity feline, then this is the game for you. Of course, like most idle games, the gameplay grows stale quickly, though the monetization in this release isn't as bad as the majority of free-to-play idle games out there.

Monetization: free / contains ads / IAPs from $1.99 - $37.99

With all the PR I received this week about Knockdown Heroes, you'd think this game was actually bringing something new to the table, but of course, it isn't. Essentially this is a title that clones the mechanics of Clash Royale, though there is a little more room for player input since there are a few unique moves in the mix. Sadly the controls aren't all that great, which really hampers player enjoyment.

Monetization: free / contains ads / IAPs from $0.99 - $49.99

RPG Liege Dragon is the latest release from Kemco to offer an English translation. As expected, this is a generic turn-based RPG that not only costs $9 but also contains in-app purchases that range all the way up to $49.99 per item. Why a $9 mobile game contains IAPS that high, I do not know, and I wouldn't recommend spending $9 to find out either. No wonder nobody talks about Kemco anymore.

Monetization: $8.99 / contains ads / IAPs from $0.99 - $49.99

Saint Seiya Shining Soldiers is the latest release from Bandai Namco, and as you can see, it's themed around the Japanese manga series Saint Seiya: Knights of the Zodiac. Like most Bandai mobile games, this is a battle-based RPG, though the UI is rough, and you'll have to constantly download new sections of the game, even if you opt for the bulk-download option, which is really annoying.

Monetization: free / no ads / IAPs from $0.99 - $79.99

Dragon Raja is a drop-dead gorgeous mobile MMO that was built using Unreal Engine 4. Much like Black Desert Mobile, this game offers a fantastic character creator, but sadly all the other annoyances found in similar MMOs make an appearance. This means auto-questing and auto-combat are present, and there doesn't appear to be an on-screen map, so auto-questing is definitely a requisite. Still, this is one of the best looking MMOs on Android to date, and it's worth exploring if you don't mind the annoyances of the genre, like heavy monetization and endless grinding.

Monetization: free / no ads / IAPs from $0.99 - $99.99

Okay, I'm just about sick of seeing all of the idle games that are constantly released on the Google Play Store. The majority are low-effort garbage that offers the exact same gameplay mechanics as the next. And then in comes Dream Blue Ocean, an idle game that actually tries to do things differently. Sure, you'll still find yourself furiously tapping on the screen during certain sections of the title, but more or less, this is a relaxing game all about fishing and exploring the ocean, and let me tell you, it looks great too. Sadly the game is still filled with ridiculous monetization, but at least its devs bothered to put some thought into its gameplay.

Monetization: free / contains ads / IAPs from $0.99 - $99.99

Bio Inc. Nemesis - Plague Doctors used to be called Bio Inc 2: Rebel Doctor Plague, and you can even see in one of the screenshots that this is indeed Bio Inc. 2. Now I don't know why the devs chose to change the name, but it would appear that the title is now officially available, despite the fact we covered the previous release at the tail end of last year. More or less, this is a virus simulation game, much like the previous title in the series, though it would appear killing humans (instead of a virus) is more of a goal this time around. So far, user reviews have not been kind, pointing to greedy monetization and buggy gameplay.

Monetization: free / contains ads / IAPs from $0.99 - $99.99

Knighthood comes from King, the developer behind the Candy Crush series, and so this release is a big departure for the company since the game is a turn-based RPG. Considering that this is a King release, you can expect extremely heavy monetization as well as a boatload of false roadblocks designed to slow down your journey. Sure, the game looks great, but that's really all it has going for it.

Monetization: free / no ads / IAPs from $1.99 - $99.99

Galaxy Airforce War is a free-to-play SHMUP that plays just like the rest. Gridining is very much a thing, and so is constant death, and for some reason, the game plays in landscape mode instead of portrait. This design choice makes it difficult to see what's going on, and for a shooter, it's detrimental to the gameplay. You know what else is detrimental, filling a SHMUP with a boatload of in-app purchases. Last I looked, there isn't a single top-down shooter on this planet worth spending $100 on.

Monetization: free / contains ads / IAPs from $2.99 - $99.99

If you have an application in mind for the next issue of the roundup, feel free to send us an email and let us know.

See more here:
25 new Android games from the week of February 24, 2020 - Android Police

Parents of son’s who suffered from cancer to take on Isle of Wight challenge – Bournemouth Echo

By Stem Cell Doctors

THE PARENTS of a boy from Poole who lost his battle with cancer three years ago are urging the public to join them on a charity walk in his memory.

Soon after celebrating his 18th birthday, Lucas Dennett was diagnosed with acute lymphoblastic leukaemia in December 2017.

Despite the best efforts of the doctors and nurses on the Durlston Ward at Poole Hospital, Lucas passed away nine months later.

In August 2017, his older brother Alex, 22, was diagnosed with Hodgkins Lymphoma. He underwent a gruelling course of chemotherapy, only for the cancer to return in December 2018, with Alex requiring a stem cell transplant.

Alex is now recovering.

Lucas and Alexs mother and stepfather, Clare and Simon Blissett, are now focused on raising as much money as possible for Leukaemia Educating and Fundraising, or LEAF, the charity that have supported them closely.

Simon, 44, said: I cant put into words what LEAF has done for our family. The charity has helped to rebuild our shattered lives.

Life will always be different for us now but thanks to LEAF we can smile, laugh and remember the good times, which is something we never thought wed be able to do.

The couple are midway through their training for the Isle of Wight Challenge in May, where theyll walk 106km non-stop around the entire coastline of the island to raise money for Dorset-based charity LEAF.

Clare and I want to do all we can to raise as much money as possible for LEAF, Simon added.

The work they do makes a huge difference to those people going through the hell of leukaemia and other forms of blood cancers.

Thats why I want as many people as possible to join us and take on the Isle of Wight Challenge in support of LEAF.

Participants can take on the full challenge of 106km in one go or complete it over two days.

Alternatively, they can take part in the half challenge of around 50km, or even the 25km quarter challenge.

LEAF supports blood cancer patients across Dorset and Hampshire.

The charitys founder, Natasha Hunt, herself a leukaemia survivor, worked closely with the the family during Lucass nine month battle with Leukaemia and Alexs battle with Hodgkins Lymphoma.

Having completed the full challenge last year in aid of The Teenage Cancer Trust, Simon wants to repeat his efforts and raise even more money for Leukaemia Educating and Fundraising.

Talking about his experience last year, Simon said: It was a great experience incredibly challenging, but so rewarding. Crossing the finishing line was such an emotional moment, knowing Id done it for Lucas.

I promised him Id raise 1million for charity, and I would love as many people as possible to join me on this walk, all raising money together in memory of our amazing son Lucas.

To sign up to the challenge and join Simons team to raise funds for LEAF, visit http://www.isleofwightchallenge.com.

If you cant join Simon and Clare for the Isle of Wight Challenge, but you still want to support them, you can sponsor them at: https://www.justgiving.com/fundraising/simon-blissett7.

Read the original post:
Parents of son's who suffered from cancer to take on Isle of Wight challenge - Bournemouth Echo

SpaceX Targeting March 6 for Launch of its 20th Resupply Mission to International Space Station | – SpaceCoastDaily.com

By Induced Pluripotent Stem Cells

coverage of launch from Cape Canaveral Air Force Station will air on Space Coast Daily TVSpaceXs Dragon lifting off on a Falcon 9 rocket from Space Launch Complex 40 at Cape Canaveral Air Force Station in Florida with research, equipment, cargo and supplies that will support dozens of investigations aboard the International Space Station. (SpaceX image)

BREVARD COUNTY CAPE CANAVERAL AIR FORCE STATION, FLORIDA NASA commercial cargo provider SpaceX is targeting 11:50 p.m. Friday, March 6, for the launch of its 20th resupply mission to the International Space Station.

Live coverage of the launch from Cape Canaveral Air Force Station in Florida will air on Space Coast Daily TV with prelaunch events Thursday, March 5 and March 6.

The NASA-contracted Dragon spacecraft will be filled with supplies and payloads, including critical materials to directly support dozens of the more than 250science and research investigationsthat will take place during Expeditions 62 and 63.

In addition to bringing research to station, the Dragons unpressurized trunk will transport ESAs (European Space Agency) Bartolomeo, a new commercial research platform set to be installed on the exterior of the orbiting laboratory.

Dragon will reach its preliminary orbit about 10 minutes after launch. It will then deploy its solar arrays and begin a carefully choreographed series of thruster firings to reach the space station.

When it arrives March 9, Expedition 62 Flight Engineer Jessica Meirof NASA will grapple Dragon, with Andrew Morganof NASA acting as a backup.

The station crew will monitor Dragon functions during rendezvous. After Dragons capture, mission control at NASAs Johnson Space Center in Houston will send ground commands for the stations arm to rotate and install it on the bottom of the stations Harmony module.

Full mission coverage is as follows (all times Eastern):

Thursday, March 5

3 p.m. NASA Social, Whats on Board science briefing from NASAs Kennedy Space Center in Florida. This briefing will highlight the following research:

Jennifer Buchli, deputy chief scientist for NASAs International Space Station Program Science Office, will share an overview of the research being conducted aboard the space station and how it benefits exploration and humanity.

Michael Roberts, interim chief scientist for the International Space Station U.S. National Laboratory, will discuss the labs work in advancing science in space, and in developing partnerships that drive industrialization through microgravity research.

Bill Corely, director of business development for Airbus Defence and Space, and Bartolomeo Project Manager Andreas Schtte, will discuss the new external science platform,Bartolomeo.

Chunhui Xu, associate professor at Emory University School of Medicine, and principal investigator for the Generation of Cardiomyocytes from Induced Pluripotent Stem Cells (MVP Cell-03) experiment, will discuss the study on the generation of specialized heart muscle cells for use in research and clinical applications. Chief Scientist of Techshot, Gene Boland, will share how the Multi-use Variable-g Platform will facilitate this experiment.

Paul Patton, senior manager, front end innovation and regulatory, for Delta Faucet, and Garry Marty, principal product engineer for Delta Faucet, will discuss theDroplet Formation Study, which evaluates water droplet formation and water flow of Delta Faucets H2Okinetic showerhead technology. This research in microgravity could help improve the technology, creating better performance and improved user experience while conserving water and energy.

Aaron Beeler, professor of medicinal chemistry at Boston University and principal investigator, and Matthew Mailloux, co-investigator, will discussFlow Chemistry Platform for Synthetic Reactions on ISS, which will study the effects of microgravity on chemical reactions, as a first step toward on-demand chemical synthesis on the space station.

Friday, March 6

4 p.m. Prelaunch news conference from Kennedy with representatives from NASAs International Space Station Program, SpaceX, and the U.S. Air Forces 45th Space Wing. Participants include:

Joel Montalbano, deputy manager for International Space Station Program

Jennifer Buchli, deputy chief scientist for International Space Station Program

Hans Koenigsmann, vice president, Build and Flight Reliability at SpaceX

Mike McAleenan, launch weather officer, U.S. Air Force 45th Space Wing

11:30 p.m. NASA TV launch coverage begins for the 11:50 p.m., launch.

Monday, March 9

4:30 a.m. NASA TV coverage begins of Dragon arrival to the station and capture. Capture is scheduled for approximately 6 a.m.

7:30 a.m. NASA TV coverage begins of Dragon installation to the nadir port of the Harmony module of the station

Dragon will remain at the space station for about four weeks, after which the spacecraft will return to Earth with research and cargo.

CLICK HERE FOR BREVARD COUNTY NEWS

Click here to contribute your news or announcements Free

Go here to see the original:
SpaceX Targeting March 6 for Launch of its 20th Resupply Mission to International Space Station | - SpaceCoastDaily.com

Animal Stem Cell Therapy Market by Segmentation Based on Product, Application and Region, 2019-2025 – Jewish Life News

By Stem Cell Clinic

Global Animal Stem Cell Therapy Market From PMRs Viewpoint

Decorated with a team of 300+ analysts, PMR Insights serves each and every requirement of the clients while preparing market reports. With digital intelligence solutions, we offer actionable insights to our customers that help them in overcoming market challenges. Our dedicated team of professionals perform an extensive survey for gathering accurate information associated with the market.

PMR, in its latest business report elaborates the current situation of the global Animal Stem Cell Therapy market in terms of volume (x units), value (Mn/Bn USD), production, and consumption. The report scrutinizes the market into various segments, end uses, regions and players on the basis of demand pattern, and future prospect.

In this Animal Stem Cell Therapy market study, the following years are considered to project the market footprint:

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

On the basis of product type, the global Animal Stem Cell Therapy market report covers the key segments,

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

The Animal Stem Cell Therapy market research addresses the following queries:

After reading the Animal Stem Cell Therapy market report, readers can

Animal Stem Cell Therapy market players Player 1, Player 2, Player 3, and Player 4, among others represent the global Animal Stem Cell Therapy market. The market study depicts an extensive analysis of all the players running in the Animal Stem Cell Therapy market report based on distribution channels, local network, innovative launches, industrial penetration, production methods, and revenue generation. Further, the market strategies, and mergers & acquisitions associated with the players are enclosed in the Animal Stem Cell Therapy market report.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

About us:

PMR is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

More:
Animal Stem Cell Therapy Market by Segmentation Based on Product, Application and Region, 2019-2025 - Jewish Life News

Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management – Zionsville…

By Stem Cell Clinic

February 2020

Are you looking for a health care provider who offers innovative alternatives and a customized approach to your health issues? Indiana Regenerative Medicine Institute (IRMI) believes in offering specialized alternatives to health care. Its medical team, headed by Doctor of Chiropractic Preston Peachee, utilizes the latest developments in regenerative medicine, hormone replacement and pain management.

Dr. Peachee is a native of Jasper, Indiana. He graduatedfrom Logan College of Chiropractic and has been in practice since 2003. Hisareas of specialty include patients with chronic and severe back, neck andjoint pain as well as other complex neurological conditions.

Dr. Peachee has earned a reputation as an innovative thinkeras well as a compassionate practitioner who brings his wide expertise andexperience to the Greater Indianapolis area. His ability to help those in needof regenerative medicine, neuropathy pain relief, low testosterone or otherphysical ailments, such as back pain or fibromyalgia, makes him not only uniquebut highly sought-after.

A key member of the IRMI team is Leann Emery, FNP. Emery isa family nurse practitioner with more than 20 years of experience in hormonereplacement and alternative pain management. Emery provides optimal patientcare through personal consultations and assessments to identify her patientsspecific health needs. She was rated in the top 10% of providers in the U.S.with patient satisfaction.

Regenerative medicine is making huge leaps in our understanding of the human body, and it is offering real, possible treatments that would have seemed like science fiction a few short years ago, according to IRMI. Most patients we see have tried other more traditional treatments and have either not gotten any better or have gotten even worse. Unfortunately, a lot of people we see depend on multiple medications per day to try and function but still are not happy with how they feel or how they live their lives. It is unfortunately the nature of deteriorating and degenerative joints, they will get worse with time, and generally the pain increases as well.

Depending on the injury, Dr. Peachee will often combinelaser therapy with the regenerative medicine protocols to improve the outcomesand try and speed the recovery process.

We offer mesenchymal stem cell therapy, Dr. Peachee said. With the combination of laser therapy, mesenchymal stem cell therapy is incredibly effective for rotator cuff problems and treating knee pain. Eighty percent of our stem patients are dealing with knee pain or Osteoarthritis. Osteoarthritis-or O.A. of the knee- is a huge problem for a lot of people, and we get great results from these therapies. Most people can even avoidknee surgery.

Dr. Peachee recently introduced hormone treatments for low testosterone. Family Nurse Practitioner Leann Emery has been doing [hormone] treatments for 20 years, and that area of medicine became a natural fit for IRMI.

I have several patients who were seeking this type ofcaremany who are police officers and firefighterswho couldnt find thetherapy and individualized care and attention that they needed.

Dr. Peachee explained that low T treatments help patients with unique and even complicated cases of Erectile Dysfunction (E.D.). Most people seek us out for treatment because they are tired, worn out, stressed out and just simply lack the energy they used to have.

We are able to fill a niche with patients who hadcomplicated cases that were not responding well with their primary careproviders or other places, Dr. Peachee shared. We have a patient who hasstruggled for a long time with fertility issues but has done very well [withtreatments], and we just got good news that he and his wife are expecting aftertrying for a really long time. So, he is really enthused about that.

The typical candidates for low T treatments, according toDr. Peachee, are men who feel worn out, are lethargic and have lost theirzest for life.

Our patients dont have the same pep that they had 10 or20 years ago, Dr. Peachee stated. They struggle getting up in the morning andmight be struggling in the afternoon after having six cups of coffee or threeRed Bulls just to get through the day. We have a lot of people that want to getback into the gym and get the maximum benefit of their workouts. We can helpthem improve their overall health and energy so that they can enjoyrecreational activities like working out or practice with the Little Leaguewith their kids. Many times we hear from spouses, friends and family how muchbetter they feel and that they seem happier and get more out of life again.

It goes without saying that proper hormonal balance canimprove a patients personal relationships as well and improve the overallmental health of a patient by reducing stress, anxiety and depression oftencaused by symptoms related to low testosterone levels.

We focus on injectable [low T] treatments because we canmodify the dosage and give more frequent doses to keep our patients at a levelthats going to give them the maximum benefit and improvement for theirconditions, Dr. Peachee explained.

With the modern changes in medicine over the last 20 and 50years, were helping people to live a lot longer and adding 20 to 30 years totheir lives, but we have not given them an improved quality of life as theyage. By working with their hormones and getting them in balance, their qualityof life becomes way better, and were seeing a positive improvement for manypeople with these treatments.

Patients suffering from severe disc injuries, such a bulgingor herniated disc or discs, or who suffer from degenerative disc disease mayhave undergone treatment from chiropractors or have seen physical therapistsbefore coming to Indiana Regenerative Medicine Institute.

Our typical patient who comes in for this type of treatmenthas seen other therapists or chiropractors but hasnt found lasting relief,Dr. Peachee said. Many of our patients want to get off the rollercoaster ofopioids and pain medications. They are looking for a solution without narcoticsand risk of addiction or other possible negative side effects of narcoticsand/or surgery. We are generally able to alleviate the pain in 90% of patientsand are able to keep them from having surgery or from taking addictivemedications.

Laser therapy allows Dr. Peachee to work on the damaged tissue so that it can heal, and the method reduces inflammation and swelling in a way that traditional treatments cannot.

Its an innovative new therapy within the last decade thatallows us to do some amazing things, Dr. Peachee stated. We perform ourprocedures in our office and have several different devices for the specificneeds and issues of our patients. For instance, we have a unique device forpeople with knee pain that can help the majority of our patients walk betterand live more pain-free. We get a phenomenal outcome with this procedure.

One of the other major differentiators that sets IndianaRegenerative Medicine Institute apart from other offices and clinics is thatthey are advocates for their patients, especially when it comes to dealing withtheir patients insurance providers.

A lot of our low T patients are able to get their insurancecarriers to cover the services so that it doesnt cost them as much out ofpocket for the care they seek, Dr. Peachee said. Weve partnered with abilling company that has helped us to be able to navigate the craziness of ourmodern insurance companies, and by doing so, were able to keep the cost downfor a lot of patients. Not every insurance plan will cover this type of care,but a lot of them will. When its possible and ethical, we do whatever we canto benefit our patients to help keep the cost low. I have spent a lot of freetime writing letters on behalf of our patients. We go above and beyond with ourservice and care of our patients.

The Indiana Regenerative Medicine Institute team will make housecalls or come to a patients place of work when the situation calls for thatlevel of care.

We will go and draw blood for blood work, bring medications and even do exams in some situations, Dr. Peachee said. As I mentioned before, we see a lot of police officers and firemen all over the statefrom Mishawaka to South Bend and all over Indiana. We go once a month to see these patients at their departments and stations so that we see them all in one day versus making 10 to 15 guys drive hours to come in to see us. Its a service we can offer because we are a small clinic and we are focused on that one-on-one patient attention and relationship building. We have great relationships with our patients, and thats something that we work very hard at.

Building trust and transparency is crucial to the success ofhis practice, Dr. Peachee emphasized. The trust that we build with ourpatients is crucial to not only the success of the practice but to thepatients outcomes. And not just with hormone therapy but also with ournonsurgical spinal decompression patients. These are patients with significant discinjuries, and we need them to tell us everything we need to know so we can givemore accurate and complete care for a better outcome.

I would say to anybody if you have any doubts or reservations to take some of the burden and some of the anxiety out of the equation and schedule an initial consultationabsolutely free of charge, Dr. Peachee encouraged.

Dont put off living your best life any longer. Visit Indiana Regenerative Medicine Institutes website at indianaregen.com or call (317) 653-4503 for more information about its services and specialized treatments and schedule your free consultationtoday!

Writer:

Janelle Morrison

Photography:

Laura Arick and submitted

The rest is here:
Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management - Zionsville...

Stem Cell Treatment

By Stem Cell Treatment

Amyotrophic Lateral Sclerosis (ALS) is a form of motor neuron disease that leads to the gradual degeneration of voluntary muscle movement. In the early stages of ALS, many of those affected have to deal with weakening of the muscles, difficulties with speaking and swallowing, and in many cases severe pain as a result. In the later stages, most patients cannot walk, talk, swallow or breathe unassisted. The figures for ALS - which is also known as Lou Gehrigs disease - are quite shocking. Read MoreAutism Spectrum Disorder (ASD) is a developmental disability, which usually lasts for the duration of a persons life. For a person with autism, the world around them is experienced in a different way, and they may find it more difficult to deal with interactions with others. This can be in the form of struggling with normal communication, but it can also mean that they find it hard to tell how other people are thinking and feeling. Read MoreOriginating in the brain, Parkinsons Disease occurs when dopamine-producing cells within the brain stop working. As a result of dopamine no longer being produced, patients with Parkinsons Disease begin experiencing a range of symptoms. Motor symptoms, such as muscle rigidity, tremors, and slowing of movement, are among the most common symptoms of Parkinsons, but patients may also experience a wide range of other symptoms as well. Common non-motor symptoms caused by Parkinsons include pain, depression, insomnia, memory problems, anxiety, and fatigue, as well as bladder and/or bowel problems. Read More

The rest is here:
Stem Cell Treatment

Stem Cell Therapy | ANOVA IRM

By Stem Cell Treatment

What is Regenerative Medicine?

Regenerative Medicine is a new field of medicine with one goal in mind: to heal and restore normal function of damaged tissues and organs. Just like the human body itself, regenerative medicine utilizes stem cells to replace damaged cells and tissues. Stem Cells are, therefore, considered to be one of the most powerful tools in treating diseases. They go beyond conventional methods to repair and regenerate disease-related damage, by returning tissues and organs to a healthier state.

Stem cells exist in many different types as they have been identified in various tissues and organs. Each type of stem cell is classified by: their origin in the body, and their potential (potency) to differentiate (transform) into other cell types. This potential varies among stem cell types.

Some stem cells are capable of differentiating themselves into any cell type of body (pluripotent). Others, on the other hand, are able to transform into many cell types (multipotent), while some are only able to differentiate themselves into few (oligopotent) or one cell type (unipotent).

Having this in mind, it is important to note that not all stem cell types are suitable for treating patients. For example, the use of Embryonic Stem Cells (ESCs) for treating patients is restricted due to ethical issues, and their potential to grow into tumors.

One of the safest and most effective forms of stem cell treatments, which we employ at ANOVA, make use of autologous stem cells, i.e. stem cells derived from the patient themselves. By using autologous stem cells for the treatment of patients, there is very minimal to no risk of tumor formation, the transmission of infectious diseases or adverse immune reactions.

Bone Marrow Concentrate (BMC) and Mesenchymal Stem Cells (MSCs) are the most abundant form of autologous adult stem cells that are well suited for clinical use. They are relatively easily harvested from the bone marrow (BMCs) or from the subcutaneous ("under the skin") fat (MSCs).

Currently, most therapies at ANOVA are based on cell-free secretion of MSCs. We are also offering combination therapies with Platelet Rich Plasma (PRP), a medium that is rich in growth factors and other cytokines (molecules from the immune system) that stimulates healing, as well as BMC in the near future. Both can additionally be supplemented with our stem cell treatments as they seamlessly synergize together.

ANOVA offers individualized stem cell therapies that are best suited for the particular condition of the patient, and for the patient only. The application of these therapies depends entirely on the patients medical condition.

Overview

Numerous types of stem cell therapies are available at ANOVA. Stem cell research brought insights that allowed for technological advancements in therapies and expanding the knowledge of the underlying mechanisms of stem cells. This has allowed for more effective therapies to be developed.

BMC

Bone Marrow Concentrate (BMC) is one of the most commonly applied source of stem cells. Despite the fact that the actual number of stem cells in BMC is biologically limited, several other (regenerative) factors in BMC have been shown to deliver promising results in the treatment of numerous diseases.

Stem Cell Secretome

Stem Cell Therapies 2.0: The ANOVA Stem Cell Secretome Therapy is the next generation of stem cell-based therapies. It was designed to harness and mass produce the healing essences of stem cells (paracrine and regenerative factors, extracellular vesicles, exosomes) in a uniquely designed laboratory process.

MSCs

Fat (adipose) derived Mesenchymal Stem Cells (MSC | adMSCs) are a commonly used source of stem cells, because of their availability and robustness. They communicate to other cells with a broad spectrum of secreted paracrine and regenerative factors. They are our favorite source of stem cells for the production of the secretome.

Platelet Rich Plasma (PRP)

Platelet Rich Plasma (PRP) is a blood-derived, cellular product with concentrated supply of regenerative growth factors and cytokines. Its efficacy has been proven in some orthopedic conditions. When used in combination with our stem cell therapies, its efficacy is synergistically enhanced.

Stem Cells, as explained previously, have the power to differentiate into any cell type, all the way from: bone cells to brain cells, heart cells, nerve cells, kidney cells, etc. This is what defines Stem Cells. However, the potency to differentiate into any body cell type is not what defines their healing powers, as not all stem cell types are able to transform into any cell type. Only a selected few, such as Bone Marrow (BMC) and Mesenchymal Stem Cells (MSCs), have been identified to differentiate into most cells type and have been successfully used in medicine to treat diseases. They have been shown to hold several major therapeutic effects, such as:

After initial damage to tissues or organs, such as mechanical forces in trauma or the lack of blood supply in strokes and heart attacks, further damage is caused by immune processes and inflammation. Subcritically injured cells, which are usually found in the vicinity of the damaged tissue or organ, primarily commit suicide instead of repairing themselves. This process further increases the damaged tissue volume. To repair this damage, which is (potentially) possible in most organs by the specific stem cells residing in them, is very slow or does not happen at all without external stimulation. In such cases, stem cells therapies have been demonstrated to be extremely effective in stimulating repair and limiting further damage.

Early stem cell research indicated that stem cells heal by replacing damaged cells in injured organs. Now, it has become evident that the major effects of tissue repair are not entirely based on direct stem cell implantation, but rather by the secretion of soluble (paracrine) factors from the stem cells themselves.

This discovery has prompted the Anova scientists to explore a completely new therapeutical approach in regenerative medicine, which has ultimately lead to the development of our novel, safe, cell-free treatment: The ANOVA's Stem Cell Secretome Therapy.

ANOVA's Stem Cell therapy method utilizes autologous stem cells, i.e. cells that are derived from the patient itself, to mass produce the secretory factors (that retain the regenerative powers of stem cells), At Anova, a minimally invasive mini-liposuction procedure is performed, which allows for the isolation of stem cells from the subcutaneous fat (adipose tissue) of the patient.

This method does not rely on direct stem cell transplantation to treat numerous diseases and support anti-aging. Latest scientific research has shown that stem cell-free therapies, such as at Anova's, offer the same efficacy as traditional stem cell transplantation therapies, with higher safety and minimized risk for the patient.

Read more:
Stem Cell Therapy | ANOVA IRM

→←